Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Opportunities to Optimize Cancer Policies Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Sep
22
Today In Oncology
Dual Oral Regimen Shows Encouraging Activity in KRAS G12C–Mutated Metastatic Colorectal Cancer
BRAF Class Alterations in NSCLC Have Different Characteristics, Outcomes, and Co-Mutations, Research Shows
AACR Releases Annual Cancer Progress Report
Plant-Based Diet Linked to Lower Risk of Prostate Cancer Progression on Active Surveillance
KEYNOTE-826 Long-Term Outcomes With Pembrolizumab Plus Chemotherapy in Advanced Cervical Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo